In current clinical practice, the CD4+ T lymphocyte count remains a cornerstone metric for assessing the degree of immunodeficiency, guiding disease staging, and informing management decisions in people living with HIV, with its prognostic value being well-established (16–18). This evidence concerns the gene CD4 and immunodeficiency disease.